SG11201401183UA - Ecm composition, tumor microenvironment platform and methods thereof - Google Patents

Ecm composition, tumor microenvironment platform and methods thereof

Info

Publication number
SG11201401183UA
SG11201401183UA SG11201401183UA SG11201401183UA SG11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA
Authority
SG
Singapore
Prior art keywords
methods
tumor microenvironment
ecm composition
microenvironment platform
platform
Prior art date
Application number
SG11201401183UA
Other languages
English (en)
Inventor
Mallikarjun Sundaram
Pradip Majumder
Biswanath Majumder
Misti Jain
Saravanan Thiagarajan
Dency Pinto
Padhma Radhakrishnan
Original Assignee
Mitra Biotech Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitra Biotech Private Ltd filed Critical Mitra Biotech Private Ltd
Publication of SG11201401183UA publication Critical patent/SG11201401183UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11201401183UA 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof SG11201401183UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04
PCT/IB2012/055334 WO2013050962A1 (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Publications (1)

Publication Number Publication Date
SG11201401183UA true SG11201401183UA (en) 2014-09-26

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401183UA SG11201401183UA (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Country Status (14)

Country Link
US (7) US20140228246A1 (enExample)
EP (1) EP2764099B1 (enExample)
JP (2) JP6147259B2 (enExample)
AU (1) AU2012320088C1 (enExample)
CA (1) CA2850274A1 (enExample)
CY (1) CY1120087T1 (enExample)
DK (1) DK2764099T3 (enExample)
ES (1) ES2660975T3 (enExample)
HU (1) HUE036537T2 (enExample)
NO (1) NO2764099T3 (enExample)
PT (1) PT2764099T (enExample)
SG (1) SG11201401183UA (enExample)
TR (1) TR201802420T4 (enExample)
WO (1) WO2013050962A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9810242B2 (en) 2013-05-31 2017-11-07 Eaton Corporation Hydraulic system and method for reducing boom bounce with counter-balance protection
US20160287533A1 (en) * 2013-11-27 2016-10-06 Research Foundation Of The City University Of New York Activity Enhancing Curcumin Compositions and Methods of Use
CN103966168B (zh) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 肿瘤活组织体外培养系统及培养方法
WO2016154082A2 (en) * 2015-03-23 2016-09-29 Tang Yao Methods of primary tissue culture and drug screening using autologous serum and fluids
US20180089363A1 (en) * 2015-04-22 2018-03-29 Ono Pharmaceutical Co., Ltd. Method for extracting lead compound, method for selecting drug discovery target, device for creating scatter diagram, and data visualization method and visualization device
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
WO2017070353A1 (en) * 2015-10-20 2017-04-27 Celcuity Llc Methods of preparing a primary cell sample
CN106047788A (zh) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的培养基
GB2555787A (en) * 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
WO2018148336A1 (en) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
WO2018185760A1 (en) 2017-04-05 2018-10-11 Yeda Research And Development Co. Ltd. Ex-vivo culture system and methods of using same
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (en) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Methods of predicting response to temporally sequenced combination therapy
GB201818885D0 (en) * 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172591A1 (en) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes
CA3130930A1 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112961830A (zh) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 口腔鳞癌组织脱细胞基质及其制备方法和应用
CA3219233A1 (en) 2021-06-06 2022-12-15 Ravid STRAUSSMAN Combined treatment for cancer
CN113774025B (zh) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 一种结直肠癌顺铂耐药株的构建方法
WO2023067582A1 (en) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression
US12312631B1 (en) 2022-06-15 2025-05-27 SageMedic Corporation High-throughput multiplexed sensitivity and resistance assay
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi
CN121320340A (zh) * 2025-07-23 2026-01-13 广西医科大学第二附属医院(广西医科大学第二临床医学院) 可抑制肿瘤生长的siRNA及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
US20120213706A1 (en) * 2009-04-15 2012-08-23 University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
US20130071864A1 (en) * 2010-05-25 2013-03-21 Makoto Watanabe Colorectal cancer marker vitronectin and method for analyzing vitronectin concentration in blood sample

Also Published As

Publication number Publication date
AU2012320088A1 (en) 2014-05-01
US20190353640A1 (en) 2019-11-21
CY1120087T1 (el) 2018-12-12
EP2764099B1 (en) 2017-11-22
US20190170730A1 (en) 2019-06-06
JP6147259B2 (ja) 2017-06-14
PT2764099T (pt) 2018-02-28
CA2850274A1 (en) 2013-04-11
EP2764099A1 (en) 2014-08-13
NO2764099T3 (enExample) 2018-04-21
JP2014534809A (ja) 2014-12-25
DK2764099T3 (en) 2018-02-26
US20190383795A1 (en) 2019-12-19
TR201802420T4 (tr) 2018-03-21
US20190383796A1 (en) 2019-12-19
JP2017061448A (ja) 2017-03-30
JP6378273B2 (ja) 2018-08-22
ES2660975T3 (es) 2018-03-26
WO2013050962A1 (en) 2013-04-11
US20190346428A1 (en) 2019-11-14
US20200064333A1 (en) 2020-02-27
AU2012320088B2 (en) 2015-07-02
HUE036537T2 (hu) 2018-07-30
US20140228246A1 (en) 2014-08-14
EP2764099A4 (en) 2015-05-06
AU2012320088B9 (en) 2015-07-16
AU2012320088C1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
IL269804A (en) Conjugates of an active protein material and a method for their preparation
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
ZA201208578B (en) Composition,method and use
HUE036462T2 (hu) Polimer készítmények és eljárások
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
HUE036537T2 (hu) ECM kompozíció, tumor-mikrokörnyezet platform és ezekhez eljárások
IL232213A0 (en) Antibody Formulations and Methods
GB201122195D0 (en) Composition and method
IL228557A0 (en) Solar absorbing formulations and related devices and methods
GB201408236D0 (en) Composition and method
GB201106433D0 (en) Composition and method
ZA201306941B (en) Use for high-molecular-weight polymer and composition including same
IL223436A (en) Methods for preparing tetranor - pgdm and tetranor - pgjm
GB201117620D0 (en) Method and composition
GB201102040D0 (en) Composition and method
GB201111496D0 (en) Composition and method
GB201116421D0 (en) Composition and method
GB201112426D0 (en) Composition and method
ZA201304786B (en) Analgesic compounds,methods,and formulations
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia
GB201001243D0 (en) Composition and method
GB201002240D0 (en) Composition and method
GB201000750D0 (en) Crop-enhancing method and composition